Publications by authors named "Ranjit Bindra"

Claim this Profile
S
Synthesis and Biological Evaluation of Colibactin Derivatives.
Yougant Airan, Olga Fedorova, Collin Heer, Matthew G Rees, Melissa M Ronan, Ranjit S Bindra

ACS Chem Biol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models.
Montserrat Puigdelloses Vallcorba, Nishant Soni, Seung-Won Choi, Kavita Rawat, Tanvi Joshi, Ranjit S Bindra

J Clin Invest· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas.
David Schiff, Xiaobu Ye, Jing Li, Benjamin M Ellingson, Patrick Y Wen, Ranjit S Bindra

Neuro Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma.
Juan C Vasquez, Ranjit S Bindra, Susan E Gueble

Med Res Arch· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions.
Linda Julian, Lisa Crozier, Devon Lukow, Sanat Mishra, Aditi Swamy, Ranjit S Bindra

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
Patrick Y Wen, Michael Weller, Eudocia Q Lee, Mehdi Touat, Mustafa Khasraw, Ranjit S Bindra

Neuro Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures.
Nalin Leelatian, Charu Singh, Richard Bouffard, Ranjini K Sundaram, Kirsten E Diggins, Ranjit S Bindra

Neuro Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer.
Elias Quijano, Diana Martinez-Saucedo, Zaira Ianniello, Natasha Pinto-Medici, Madison Rackear, Ranjit S Bindra

Sci Transl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.
Matthew McCord, Thomas Sears, Wenxia Wang, Rahul Chaliparambil, Shejuan An, Ranjit Bindra

Neuro Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, Nilofer S Azad, May Cho, Ranjit Bindra

Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.
Mary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, Mehdi Touat, Enrico Franceschi, Ranjit S Bindra

Neuro Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARG inhibition induces nuclear aggregation of PARylated PARP1.
Sateja Paradkar, Julia Purcell, Annie Cui, Sam Friedman, Katelyn J Noronha, Ranjit S Bindra

Structure· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion.
Katelyn J Noronha, Karlie N Lucas, Sateja Paradkar, Joseph Edmonds, Sam Friedman, Ranjit S Bindra

Mol Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors.
Matthew A Murray, Katelyn J Noronha, Yazhe Wang, Anna P Friedman, Sateja Paradkar, Ranjit S Bindra

Mol Cancer Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
Rifaquat Rahman, Diana D Shi, Zachary J Reitman, Petra Hamerlik, John F de Groot, Ranjit S Bindra

Neuro Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.
Eric D Huseman, Anna Lo, Olga Fedorova, James L Elia, Susan E Gueble, Ranjit S Bindra

J Am Chem Soc· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma.
Minsoo Khang, Ju Hyun Lee, Teresa Lee, Hee-Won Suh, Supum Lee, Ranjit S Bindra

Sci Transl Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum Sensitivity in Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.
Deborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, Daniella Sia, Joseph Paul Eder, Ranjit Bindra

Cancer Invest· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors.
Suzanne Xu, Allison Campbell, Veronica Chiang, Ranjit Bindra, Juan Vasquez

Pediatr Blood Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Michael Cecchini, Janie Y Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Ranjit S Bindra

Cancer Res Commun· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Yazhe Wang, Shipra Malik, Hee-Won Suh, Yong Xiao, Yanxiang Deng, Ranjit S Bindra

Sci Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent and -mutant Glioma.
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Ranjit S Bindra

Cancer Res Commun· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Ranjit Bindra

Neuro Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Amar Gajjar, Anita Mahajan, Mohamed Abdelbaki, Clarke Anderson, Reuben Antony, Ranjit Bindra

J Natl Compr Canc Netw· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
Susan E Gueble, Juan C Vasquez, Ranjit S Bindra

Curr Treat Options Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis